STMN Stock Analysis: Straumann Holding | SW
Medical Instruments & Supplies | SW, Switzerland | Market Cap: 14.829m CHF | 12M Return: 1.8% | CH1175448666 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.4M
Qual. Beats: 0
Rev. Trend: 100.0%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Straumann Holding AG, headquartered in Basel and founded in 1954, is a global provider of tooth replacement and orthodontic solutions, operating across Europe, the Americas, and Asia Pacific through four regional sales segments and a dedicated operations segment. Its portfolio spans dental implants, CADCAM prosthetics, clear aligners, biomaterials, intra-oral scanners, milling machines, 3D printers, guided surgery systems, consumables, and regenerative products, supported by customer training, online education, and logistics services. Products are marketed under multiple brands, including Straumann, Neodent, Medentika, Anthogyr, and ClearCorrect, and distributed via subsidiaries, partners, third-party distributors, and an e-shop. As a major player in the dental equipment and consumables industry, the company sits within the broader medical devices sector, where demand is driven by demographic trends such as aging populations, growing aesthetic dentistry adoption, and the ongoing digitalization of dental workflows.
- China implant market growth fuels Asia Pacific segment expansion
- ClearCorrect clear aligners compete against Invisalign in value segment
- Swiss franc appreciation pressures reported revenue and operating margins
| Net Income: 370.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -0.18 > 1.0 |
| NWC/Revenue: 36.38% < 20% (prev 22.29%; Δ 14.09% < -1%) |
| CFO/TA 0.13 > 3% & CFO 524.8m > Net Income 370.5m |
| Net Debt (299.1m) to EBITDA (685.9m): 0.44 < 3 |
| Current Ratio: 2.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (159.7m) vs 12m ago 0.15% < -2% |
| Gross Margin: 68.26% > 18% (prev 70.91%; Δ -2.64% > 0.5%) |
| Asset Turnover: 71.16% > 50% (prev 73.43%; Δ -2.28% > 0%) |
| Interest Coverage Ratio: 3.50 > 6 (EBIT TTM 525.1m / Interest Expense TTM 150.2m) |
| A: 0.25 (Total Current Assets 1.72b - Total Current Liabilities 759.1m) / Total Assets 3.90b |
| B: 0.77 (Retained Earnings 2.98b / Total Assets 3.90b) |
| C: 0.14 (EBIT TTM 525.1m / Avg Total Assets 3.70b) |
| D: 1.41 (Book Value of Equity 2.28b / Total Liabilities 1.61b) |
| Altman-Z'' = 6.55 = AAA |
| DSRI: 1.23 (Receivables 805.6m/641.0m, Revenue 2.64b/2.58b) |
| GMI: 1.04 (GM 70.91% / 68.26%) |
| AQI: 0.97 (AQ_t 0.36 / AQ_t-1 0.38) |
| SGI: 1.02 (Revenue 2.64b / 2.58b) |
| TATA: -0.04 (NI 370.5m - CFO 524.8m) / TA 3.90b) |
| Beneish M = -2.81 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at CHF 89.84 with a total of 327,516 shares traded. Over the past week, the price has changed by +0.04%, over one month by -3.58%, over three months by -13.32% and over the past year by +1.77%.
Current recommended Stop Loss: 84.60 (which is 5.8% or 2 ATR below the current price).
Straumann Holding has no consensus analysts rating.
P/E Trailing = 40.2597
P/E Forward = 26.1097
P/S = 5.6241
P/B = 6.7963
P/EG = 1.2548
Revenue TTM = 2.64b CHF
EBIT TTM = 525.1m CHF
EBITDA TTM = 685.9m CHF
Long Term Debt = 249.7m CHF (from longTermDebt, last fiscal year)
Short Term Debt = 36.3m CHF (from shortTermDebt, last quarter)
Debt = 680.1m CHF (from shortLongTermDebtTotal, last quarter) + Leases 169.2m
Net Debt = 299.1m CHF (calculated: Debt 680.1m - CCE 381.0m)
Enterprise Value = 15.1b CHF (14.8b + Debt 680.1m - CCE 381.0m)
Interest Coverage Ratio = 3.50 (Ebit TTM 525.1m / Interest Expense TTM 150.2m)
EV/FCF = 39.49x (Enterprise Value 15.1b / FCF TTM 383.0m)
FCF Yield = 2.53% (FCF TTM 383.0m / Enterprise Value 15.1b)
FCF Margin = 14.53% (FCF TTM 383.0m / Revenue TTM 2.64b)
Net Margin = 14.05% (Net Income TTM 370.5m / Revenue TTM 2.64b)
Gross Margin = 68.26% ((Revenue TTM 2.64b - Cost of Revenue TTM 836.6m) / Revenue TTM)
Gross Margin QoQ = 71.38% (prev 64.85%)
Tobins Q-Ratio = 3.88 (Enterprise Value 15.1b / Total Assets 3.90b)
Interest Expense / Debt = 22.08% (Interest Expense 150.2m / Debt 680.1m)
Taxrate = 22.14% (105.4m / 475.9m)
NOPAT = 408.8m (EBIT 525.1m * (1 - 22.14%))
Current Ratio = 2.26 (Total Current Assets 1.72b / Total Current Liabilities 759.1m)
Debt / Equity = 0.30 (Debt 680.1m / totalStockholderEquity, last quarter 2.28b)
Debt / EBITDA = 0.44 (Net Debt 299.1m / EBITDA 685.9m)
Debt / FCF = 0.78 (Net Debt 299.1m / FCF TTM 383.0m)
Total Stockholder Equity = 2.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.00% (Net Income 370.5m / Total Assets 3.90b)
RoE = 17.36% (Net Income TTM 370.5m / Total Stockholder Equity 2.13b)
RoCE = 22.02% (EBIT 525.1m / Capital Employed (Equity 2.13b + L.T.Debt 249.7m))
RoIC = 13.43% (NOPAT 408.8m / Invested Capital 3.04b)
WACC = 9.36% (E(14.8b)/V(15.5b) * Re(9.0%) + D(680.1m)/V(15.5b) * Rd(22.08%) * (1-Tc(0.22)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -26.03 | Cagr: 0.02%
[DCF] Terminal Value 73.20% ; FCFF base≈370.4m ; Y1≈399.7m ; Y5≈489.0m
[DCF] Fair Price = 38.15 (EV 6.38b - Net Debt 299.1m = Equity 6.08b / Shares 159.5m; r=9.36% [WACC]; 5y FCF grow 9.03% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.03 | # QB: 0
Revenue Correlation: 99.99 | Revenue CAGR: 3.93% | SUE: 1.24 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=3.27 | Chg30d=+0.92% | Revisions=+29% | GrowthEPS=+9.9% | GrowthRev=+6.4%
EPS next Year (2027-12-31): EPS=3.86 | Chg30d=+1.37% | Revisions=+62% | GrowthEPS=+17.7% | GrowthRev=+10.2%
[Analyst] Revisions Ratio: +58% (up=8, down=1)